Kraig Biocraft Laboratories, Inc. (KBLB)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kraig Biocraft Laboratories, Inc. (KBLB) with AI Score 44/100 (Weak). Kraig Biocraft Laboratories, Inc. develops protein-based fibers using recombinant DNA technology. Market cap: 0, Sector: Basic materials.
Last analyzed: Mar 17, 2026Kraig Biocraft Laboratories, Inc. (KBLB) Materials & Commodity Exposure
Kraig Biocraft Laboratories, Inc. specializes in developing and commercializing protein-based fibers, leveraging recombinant DNA technology for applications in technical textiles and specialty fibers. Targeting diverse sectors including defense, industrial, and medical, the company aims to disrupt traditional material science with innovative, high-performance solutions.
Investment Thesis
Kraig Biocraft Laboratories presents a high-risk, high-reward investment opportunity centered on its proprietary spider silk technology. The company's potential lies in disrupting the technical textile and specialty fiber markets with a sustainable, high-performance alternative to traditional materials. Key value drivers include successful scaling of spider silk production, securing significant contracts in target markets such as defense and aerospace, and achieving profitability. However, the company's negative profit margin of -13698.5% and negative gross margin of -15.1% highlight significant financial challenges. Upcoming catalysts include potential advancements in production efficiency and new partnerships. Investors should closely monitor the company's ability to secure funding and achieve commercial viability.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.13 billion indicates a small-cap company with potential for growth but also higher volatility.
- P/E ratio of -35.29 reflects the company's current lack of profitability, suggesting it is an early-stage growth company.
- Profit Margin of -13698.5% highlights significant operational inefficiencies and challenges in achieving profitability.
- Gross Margin of -15.1% indicates that the company's cost of goods sold exceeds its revenue, requiring substantial improvements in production efficiency.
- Beta of 1.33 suggests the stock is more volatile than the market, indicating higher risk and potential for larger price swings.
Competitors & Peers
Strengths
- Proprietary spider silk technology.
- Potential for high-performance materials.
- Sustainable and eco-friendly production process.
- Diverse range of potential applications.
Weaknesses
- Negative profit margin and gross margin.
- Limited commercial production capacity.
- Reliance on successful scaling of production.
- Competition from established material companies.
Catalysts
- Upcoming: Potential advancements in spider silk production efficiency.
- Upcoming: Securing new contracts in the defense or aerospace sectors.
- Ongoing: Research and development efforts to expand applications of spider silk.
- Ongoing: Partnerships with industry leaders to commercialize spider silk products.
- Ongoing: Efforts to improve financial performance and achieve profitability.
Risks
- Ongoing: Negative profit margin and gross margin indicate financial instability.
- Potential: Competition from established material companies.
- Potential: Technological advancements by competitors.
- Potential: Regulatory hurdles and compliance requirements.
- Ongoing: Reliance on successful scaling of spider silk production.
Growth Opportunities
- Growth opportunity 1: Expansion into the defense and military textiles market represents a significant growth opportunity for Kraig Biocraft. Spider silk's exceptional strength and ballistic protection capabilities make it an ideal material for body armor and other protective gear. Securing contracts with defense agencies could drive substantial revenue growth. The global military textiles market is projected to reach billions of dollars, offering a large addressable market for Kraig Biocraft. Timeline: Ongoing.
- Growth opportunity 2: Penetration of the aerospace composite materials market offers another avenue for growth. Spider silk can be used to reinforce composite materials, enhancing their strength and durability while reducing weight. This is particularly valuable in the aerospace industry, where weight reduction translates to fuel efficiency and improved performance. The aerospace composite materials market is expected to grow, driven by increasing demand for lightweight and fuel-efficient aircraft. Timeline: Ongoing.
- Growth opportunity 3: Development of medical textile applications for spider silk presents a high-value growth opportunity. Spider silk's biocompatibility and strength make it suitable for sutures, wound dressings, and tissue scaffolds. The medical textiles market is growing, driven by advancements in healthcare technology and increasing demand for biocompatible materials. Kraig Biocraft can partner with medical device companies to develop and commercialize spider silk-based medical products. Timeline: Ongoing.
- Growth opportunity 4: Licensing of Kraig Biocraft's spider silk technology to other companies in the textile and materials industries could generate significant revenue streams. Licensing agreements would allow other companies to utilize Kraig Biocraft's technology to develop and commercialize their own spider silk-based products. This strategy would expand the reach of Kraig Biocraft's technology and generate recurring revenue. Timeline: Ongoing.
- Growth opportunity 5: Improving production efficiency and scaling up spider silk production is crucial for achieving profitability and meeting market demand. Investing in research and development to optimize silkworm breeding and silk extraction processes can significantly reduce production costs and increase output. This will enable Kraig Biocraft to compete more effectively with traditional materials and capture a larger share of the market. Timeline: Ongoing.
Opportunities
- Expansion into defense, aerospace, and medical markets.
- Licensing of spider silk technology.
- Partnerships with industry leaders.
- Increasing demand for sustainable materials.
Threats
- Competition from alternative materials.
- Technological advancements by competitors.
- Regulatory hurdles and compliance requirements.
- Economic downturn affecting demand for specialty materials.
Competitive Advantages
- Proprietary recombinant DNA technology for spider silk production.
- Patents protecting its spider silk technology.
- First-mover advantage in the spider silk market.
- Potential for strong brand recognition as a leader in advanced materials.
About KBLB
Kraig Biocraft Laboratories, Inc., founded in 2006 and headquartered in Ann Arbor, Michigan, is a biotechnology company focused on the development and commercialization of protein-based fibers. The company utilizes recombinant DNA technology to create advanced materials with unique properties, targeting the technical textile and specialty fiber industries. Kraig Biocraft's core innovation lies in genetically engineering silkworms to produce spider silk, a material known for its exceptional strength, elasticity, and toughness. These spider silk-based fibers are designed for a wide range of applications, including ballistic protection, industrial cables, safety equipment, and composite materials for the aerospace industry. The company's products also cater to niche markets such as medical textiles, geotextiles, defense and military textiles, protective clothing, filtration textiles, and functional textiles for buildings and transportation. Kraig Biocraft aims to replace traditional materials with sustainable, high-performance alternatives, positioning itself as a key player in the advanced materials sector.
What They Do
- Develops protein-based fibers using recombinant DNA technology.
- Engineers silkworms to produce spider silk.
- Creates advanced materials with unique properties.
- Targets the technical textile and specialty fiber industries.
- Offers spider silk-based fibers for ballistic protection.
- Provides materials for industrial cables and safety equipment.
- Develops composite materials for the aerospace industry.
Business Model
- Develops and patents recombinant DNA technology for spider silk production.
- Produces spider silk fibers through genetically engineered silkworms.
- Sells spider silk fibers to manufacturers in various industries.
- Potentially licenses its technology to other companies for revenue.
Industry Context
Kraig Biocraft Laboratories operates within the specialty chemicals industry, a sector characterized by innovation in material science and increasing demand for high-performance and sustainable materials. The technical textile market, a key target for Kraig Biocraft, is projected to grow, driven by advancements in material technology and increasing applications in defense, aerospace, and healthcare. Competition includes established chemical companies and emerging biotech firms focused on advanced materials. Kraig Biocraft aims to differentiate itself through its proprietary spider silk technology, offering a unique combination of strength, elasticity, and sustainability.
Key Customers
- Manufacturers of ballistic protection equipment.
- Companies producing industrial cables and safety equipment.
- Aerospace companies using composite materials.
- Medical device companies requiring biocompatible materials.
Financials
Chart & Info
Kraig Biocraft Laboratories, Inc. (KBLB) stock price: Price data unavailable
Latest News
No recent news available for KBLB.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KBLB.
Price Targets
Wall Street price target analysis for KBLB.
MoonshotScore
What does this score mean?
The MoonshotScore rates KBLB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kim Kraig Thompson
CEO
Kim Kraig Thompson serves as the CEO of Kraig Biocraft Laboratories, Inc. His background includes experience in business management and strategic development. He has been instrumental in guiding the company's focus on recombinant DNA technology and the commercialization of spider silk. Thompson's leadership is centered on driving innovation and expanding the applications of the company's unique materials.
Track Record: Under Kim Kraig Thompson's leadership, Kraig Biocraft Laboratories has focused on developing and patenting its spider silk technology. Key milestones include securing patents for its recombinant DNA processes and establishing partnerships to explore commercial applications. Thompson has overseen the company's efforts to scale up production and target key markets such as defense and aerospace.
KBLB OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Kraig Biocraft Laboratories may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with higher risk profiles and speculative ventures.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility.
- Higher risk of fraud or manipulation compared to listed exchanges.
- OTC Other tier status indicates potential financial or operational challenges.
- Regulatory oversight is less stringent than on major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patents.
- Check for any legal or regulatory issues.
- Monitor trading volume and price volatility.
- Consult with a financial advisor.
- Patents protecting its spider silk technology.
- Focus on developing high-performance materials.
- Targeting diverse markets including defense and aerospace.
- CEO with relevant experience in business management.
- Company has been in operation since 2006.
What Investors Ask About Kraig Biocraft Laboratories, Inc. (KBLB)
What does Kraig Biocraft Laboratories, Inc. do?
Kraig Biocraft Laboratories, Inc. is a biotechnology company that specializes in developing protein-based fibers using recombinant DNA technology. The company's primary focus is on producing spider silk through genetically engineered silkworms. This spider silk is then used to create advanced materials for various applications, including ballistic protection, industrial cables, safety equipment, and composite materials for the aerospace industry. The company aims to replace traditional materials with sustainable, high-performance alternatives.
What do analysts say about KBLB stock?
As of 2026-03-17, there is no available analyst consensus on Kraig Biocraft Laboratories, Inc. (KBLB). The company's financial metrics, including a negative profit margin of -13698.5% and a negative gross margin of -15.1%, suggest significant financial challenges. Investors should carefully consider the company's high-risk, high-reward profile, potential for disruption in the technical textile market, and ability to achieve commercial viability before making any investment decisions.
What are the main risks for KBLB?
The main risks for Kraig Biocraft Laboratories, Inc. include its current financial instability, as evidenced by its negative profit and gross margins. The company faces competition from established material companies and the potential for technological advancements by competitors. Regulatory hurdles and compliance requirements could also pose challenges. Additionally, the company's success depends on its ability to successfully scale up spider silk production and secure significant contracts in its target markets.
What are the key factors to evaluate for KBLB?
Kraig Biocraft Laboratories, Inc. (KBLB) currently holds an AI score of 44/100, indicating low score. Key strength: Proprietary spider silk technology.. Primary risk to monitor: Ongoing: Negative profit margin and gross margin indicate financial instability.. This is not financial advice.
How frequently does KBLB data refresh on this page?
KBLB prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven KBLB's recent stock price performance?
Recent price movement in Kraig Biocraft Laboratories, Inc. (KBLB) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary spider silk technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider KBLB overvalued or undervalued right now?
Determining whether Kraig Biocraft Laboratories, Inc. (KBLB) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying KBLB?
Before investing in Kraig Biocraft Laboratories, Inc. (KBLB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited or less reliable than data from major exchanges.